초록 ▼

Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or b

Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.

대표청구항 ▼

We claim: 1. A fusion molecule comprising: a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen-binding fragment thereof that binds to CD200 comprising (i) a light chain CDR1 having the sequence set forth in residues 26-36

We claim: 1. A fusion molecule comprising: a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen-binding fragment thereof that binds to CD200 comprising (i) a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO: 208, (ii) a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO: 208, (iii) a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO: 208, (iv) a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 114, (v) a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 165, and (vi) a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 189; and a second portion that promotes the death of cells, wherein the second portion is a toxin. 2. The fusion molecule of claim 1, wherein the first portion comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 202. 3. A chimeric anti-CD200 antibody or antigen-binding fragment thereof that binds to CD200, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 202 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 208. 4. An anti-CD200 antibody or antigen-binding fragment thereof that binds to CD200, wherein the antibody or antigen-binding fragment comprises: a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO: 208; a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO: 208; a light chain having the sequence set forth in residues 26-36 of SEQ ID NO: 208; a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 189; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 165; and a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 114. 5. The antibody or antigen-binding fragment of claim 4, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 202. 6. The antibody or antigen-binding fragment of claim 4, wherein the antibody or antigen-binding fragment comprises a light chain variable region having the sequence set forth in SEQ ID NO: 208. 7. The antibody or antigen-binding fragment of claim 4, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 202 and a light chain variable region having the sequence set forth in SEQ ID NO: 208. 8. The antibody or antigen-binding fragment of claim 4, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, and a chimeric antibody. 9. The antigen-binding fragment of claim 4, wherein the antigen-binding fragment is selected from the group consisting of an Fv, scFv, Fab′ and F(ab′)2. 10. The antigen-binding fragment of claim 9, wherein the antigen-binding fragment is a humanized antigen-binding fragment. 11. A composition comprising an antibody or antigen-binding fragment thereof of claim 4 and a pharmaceutically acceptable carrier. 12. The fusion molecule of claim 1, wherein said toxin is selected from the group consisting of a plant toxin, a fungal toxin, a bacterial toxin, a cytotoxic drug, a radioactive isotope, an immunoglobulin constant region having antibody-dependent cellular cytotoxicity (ADCC) activity, and an immunoglobulin constant region having complement dependent cytotoxicity (CDC) activity. 13. The fusion molecule of claim 1, wherein the first portion comprises a light chain variable region having the sequence set forth in SEQ ID NO: 208. 14. The fusion molecule of claim 1, wherein the first portion comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 202 and a light chain variable region having the sequence set forth in SEQ ID NO: 208. 15. The fusion molecule of claim 1, wherein the antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, and a chimeric antibody. 16. The fusion molecule of claim 1, wherein the antigen-binding fragment is selected from the group consisting of an Fv, scFv, Fab′ and F(ab′)2. 17. The fusion molecule of claim 1, wherein the antigen-binding fragment is a humanized antigen-binding fragment.